
Bioorganic and Medicinal Chemistry Letters p. 853 - 856 (1999)
Update date:2022-08-05
Topics:
Vince, Robert
Brownell, Jay
Akella, Lakshmi B.
The inhibition of glyoxalase I enzyme to increase cellular levels of methylglyoxal has been developed as a rationale for the production of anticancer agents. Synthesis of a peptidomimetic analog of the previously prepared potent glyoxalase inhibitor, S-(p-bromobenzyl)glutathione (PBBG), was accomplished by inserting a urea linkage, NH-CO-NH, to replace the γ- glutamyl peptide bond. Thus, the target compound, γ-(L-γ-azaglutamyl)-S- (p-bromobenzyl)-L-cysteinylglycine 6, was a potent inhibitor of glyoxalase I with almost no loss of activity when compared to PBBG. However, unlike PBBG, 6 was completely resistant to enzymatic degradation by kidney homogenate or by purified γ-glutamyltranspeptidase enzyme.
View MoreLiaoning Yufeng Chemical Co.,Ltd.
Contact:86-0419-3418888
Address:The metallurgical industrial zone,shoushan town, Liaoyang, Liaoning, China
JiYi Chemical (Beijing) Co., Ltd.
Contact:+86-10-89385733
Address:Shilou Town of Fangshan District, Beijing
Contact:0571-
Address:zhejing
Hangzhou Bayee Chemical Co.,Ltd.
Contact:+86-571-86990109
Address:No.380, Jiangnan Auenue, Binjiang District, Hangzhou, China
HUNAN CHEMAPI BIOLOGICAL TECHNOLOGY CO.,LTD.
Contact:+86-186-02659358
Address:1004, building 3, Wanke Jinsemaitianyuan, 498 Guitang Road, Yuhua District, Changsha City, Hunan Province, China
Doi:10.1016/j.tet.2013.10.024
(2013)Doi:10.1055/s-2001-18706
(2001)Doi:10.1016/S0022-328X(00)86348-2
(1968)Doi:10.1021/ic50075a007
(1969)Doi:10.1016/S0040-4039(01)88000-X
(1969)Doi:10.1021/om990023q
(1999)